2398. Utilization Practices of Ceftazidime–Avibactam at Academic Medical Centers in the United States

BACKGROUND: Ceftazidime–avibactam (CAV) was US FDA-approved for complicated intra-abdominal/urinary tract infections in 2015, and for hospital-acquired/ventilator-associated pneumonia in 2018. However, little is known about its real-world use. METHODS: Encounters of inpatients receiving CAV at acade...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Strich, Jeffrey R, Ricotta, Emily, Lai, Yi Ling, Hohmann, Samuel, Hussain, Sadia, Rhee, Chanu, Klompas, Michael, Palmore, Tara N, III, John H Powers, Dekker, John P, Adjemian, Jennifer, Danner, Robert L, Kadri, Sameer S
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6253798/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.2051
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars